Industry

– U.S. FDA Study May Proceed notification enables initiation of clinical trial site activation for the FUNCTION-DMD Phase 1/2 clinical study in patients with Duchenne muscular dystrophy (DMD) – – Institutional Review Board (IRB) process is underway at multiple world-class DMD clinical trial sites – – PBGENE-DMD is an in vivo gene editing investigational product … [Read more…]

The 2026 Love and Money Benchmark Survey compares 2025 and 2026 data to reveal how financial pressures are increasingly straining Canadian relationships and dating lives year-over-year. CALGARY, Alberta–(BUSINESS WIRE)–As affordability pressures continue to weigh on households across the country, financial stress is taking a growing toll on Canadians’ relationships. According to the 2026 Love and … [Read more…]

Restylane® Refyne™ and Restylane Defyne™ are the first Optimal Balance Technology (OBT™) hyaluronic acid injectables ever approved and launched in Japan, bringing advanced flexibility and natural movement to the market1,2 This expands Galderma’s Restylane portfolio in Japan to four products, enabling treatment of a wider spectrum of patient and practitioner needs3,4 These two new launches … [Read more…]

Elecoglipron demonstrated a favorable safety and tolerability profile in Chinese adults living with obesity/overweight with or without type 2 diabetes mellitus (T2DM), consistent with that of the GLP-1 receptor agonist class Pharmacokinetic results in this study were comparable with the prior data generated from global Phase 1 clinical studies, supporting potential use of a consistent … [Read more…]

FOSTER CITY, Calif.–(BUSINESS WIRE)–#Dividend–Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company’s Board of Directors has declared an increase of 3.8% in the company’s quarterly cash dividend, beginning in the first quarter of 2026. The increase will result in a quarterly dividend of $0.82 per share of common stock. The dividend is payable on … [Read more…]

GENTILLY, France–(BUSINESS WIRE)–THX Pharma (Theranexus) and Biocodex, an independent international pharmaceutical group, today announced the execution of a strategic licensing agreement to advance the development of two drug candidates in three rare diseases with high unmet medical needs: Batten disease with Batten-1, and Gaucher disease and Niemann-Pick type C disease with TX01. Under the agreement, … [Read more…]

The breakthrough formula starts to repair sensitive areas of teeth after 60 seconds for substantial sensitivity relief in 3 days, delivering long-lasting relief with twice-daily brushing Key Takeaways Sensodyne unveils Clinical Repair, the brand’s newest toothpaste option for sensitive teeth. Clinical Repair: Starts to repair sensitive areas of teeth after 60 seconds* for clinically proven … [Read more…]

Strong commercial performance and excellent pipeline delivery in a continuing catalyst-rich period CAMBRIDGE, England–(BUSINESS WIRE)–AstraZeneca: Revenue and EPS summary   FY 2025 % Change Q4 2025 % Change   $m Actual CER1 $m Actual CER – Product Sales 55,573 9 9 14,538 9 7 – Alliance Revenue 3,067 39 38 959 34 33 Product Revenue2 … [Read more…]

CHELMSFORD, Mass.–(BUSINESS WIRE)–ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that Zenix®, the company’s most clinically advanced and easy-to-use professional monitor/defibrillator, is approved under the European Union (EU) Medical Device Regulation 2017/745, commonly referred to as EU MDR. The Zenix monitor/defibrillator is a groundbreaking device that redefines efficiency, … [Read more…]

– Funding secured, extending the financial runway to reach a proof-of-concept inflection point – Company’s attractiveness reinforced through the onboarding of new investors LILLE, France & PARIS–(BUSINESS WIRE)–4Moving Biotech (4MB), a clinical-stage biotechnology company and a spin-off of 4P-Pharma, developing a first-in-class disease-modifying osteoarthritis drug (DMOAD) for knee osteoarthritis, today announced the closing of a … [Read more…]